JP2022502516A5 - - Google Patents

Info

Publication number
JP2022502516A5
JP2022502516A5 JP2021545281A JP2021545281A JP2022502516A5 JP 2022502516 A5 JP2022502516 A5 JP 2022502516A5 JP 2021545281 A JP2021545281 A JP 2021545281A JP 2021545281 A JP2021545281 A JP 2021545281A JP 2022502516 A5 JP2022502516 A5 JP 2022502516A5
Authority
JP
Japan
Prior art keywords
angles selected
pxrd peaks
iii
pxrd
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545281A
Other languages
English (en)
Japanese (ja)
Other versions
JP7476214B2 (ja
JP2022502516A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056242 external-priority patent/WO2020081514A1/en
Publication of JP2022502516A publication Critical patent/JP2022502516A/ja
Publication of JP2022502516A5 publication Critical patent/JP2022502516A5/ja
Application granted granted Critical
Publication of JP7476214B2 publication Critical patent/JP7476214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545281A 2018-10-15 2019-10-15 ブルトン型チロシンキナーゼ阻害剤の結晶多形 Active JP7476214B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745741P 2018-10-15 2018-10-15
US62/745,741 2018-10-15
PCT/US2019/056242 WO2020081514A1 (en) 2018-10-15 2019-10-15 Crystalline polymorphs of bruton's tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2022502516A JP2022502516A (ja) 2022-01-11
JP2022502516A5 true JP2022502516A5 (cg-RX-API-DMAC7.html) 2022-10-21
JP7476214B2 JP7476214B2 (ja) 2024-04-30

Family

ID=68426868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545281A Active JP7476214B2 (ja) 2018-10-15 2019-10-15 ブルトン型チロシンキナーゼ阻害剤の結晶多形

Country Status (5)

Country Link
US (1) US11820760B2 (cg-RX-API-DMAC7.html)
EP (1) EP3866926A1 (cg-RX-API-DMAC7.html)
JP (1) JP7476214B2 (cg-RX-API-DMAC7.html)
MA (1) MA53914A (cg-RX-API-DMAC7.html)
WO (1) WO2020081514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2025013208A (es) * 2023-05-05 2026-02-03 Biogen Ma Inc Inhibidor de btk para el tratamiento de la esclerosis múltiple

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
BR112015007513A2 (pt) 2012-10-26 2017-07-04 Hoffmann La Roche inibidores de tirosina quinase de bruton
US10329270B2 (en) * 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
RS65386B1 (sr) * 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
WO2019222101A1 (en) 2018-05-14 2019-11-21 Biogen Ma Inc. Inhibiting agents for bruton's tyrosine kinase

Similar Documents

Publication Publication Date Title
JPWO2022234864A5 (cg-RX-API-DMAC7.html)
JP2022186995A5 (cg-RX-API-DMAC7.html)
JP2023116503A5 (cg-RX-API-DMAC7.html)
JP2021530565A5 (cg-RX-API-DMAC7.html)
JP2023519891A5 (cg-RX-API-DMAC7.html)
JP2019508407A5 (cg-RX-API-DMAC7.html)
JP2023036708A5 (cg-RX-API-DMAC7.html)
JP2020512316A5 (cg-RX-API-DMAC7.html)
JP2007514746A5 (cg-RX-API-DMAC7.html)
HRP20240361T1 (hr) Analozi benzoazepina kao sredstva za inhibiciju brutonove tirozin kinaze
JP6008937B2 (ja) 1−(3−シアノ−1−イソプロピル−インドール−5−イル)ピラゾール−4−カルボン酸の結晶形とその製造方法
JP5184511B2 (ja) 新しい結晶形態のラミブジン
AU2017382405A1 (en) Compositions and methods for inhibiting arginase activity
JP2016515545A5 (cg-RX-API-DMAC7.html)
CN110573500A (zh) N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用
JP2016512515A5 (cg-RX-API-DMAC7.html)
RU2014145544A (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
JP2023522040A5 (cg-RX-API-DMAC7.html)
JP2020516659A5 (cg-RX-API-DMAC7.html)
JP2007515489A5 (cg-RX-API-DMAC7.html)
JP2022551525A5 (cg-RX-API-DMAC7.html)
JP2020502224A5 (cg-RX-API-DMAC7.html)
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
JP2021535111A5 (cg-RX-API-DMAC7.html)
JPWO2021033729A5 (cg-RX-API-DMAC7.html)